PortalPublikationenFlavopiridol protects against inflammation by attenuating le...

Flavopiridol protects against inflammation by attenuating leukocyte-endothelial interaction via inhibition of cyclin-dependent kinase 9.

Standard

Flavopiridol protects against inflammation by attenuating leukocyte-endothelial interaction via inhibition of cyclin-dependent kinase 9. / Schmerwitz, Ulrike K; Sass, Gabriele; Khandoga, Alexander G; Joore, Jos; Mayer, Bettina A; Berberich, Nina; Totzke, Frank; Krombach, Fritz; Tiegs, Gisa; Zahler, Stefan; Vollmar, Angelika M; Fürst, Robert.

in: ARTERIOSCL THROM VAS, Jahrgang 31, Nr. 2, 2, 2011, S. 280-288.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Schmerwitz, UK, Sass, G, Khandoga, AG, Joore, J, Mayer, BA, Berberich, N, Totzke, F, Krombach, F, Tiegs, G, Zahler, S, Vollmar, AM & Fürst, R 2011, 'Flavopiridol protects against inflammation by attenuating leukocyte-endothelial interaction via inhibition of cyclin-dependent kinase 9.', ARTERIOSCL THROM VAS, Jg. 31, Nr. 2, 2, S. 280-288. <http://www.ncbi.nlm.nih.gov/pubmed/21088252?dopt=Citation>

APA

Schmerwitz, U. K., Sass, G., Khandoga, A. G., Joore, J., Mayer, B. A., Berberich, N., Totzke, F., Krombach, F., Tiegs, G., Zahler, S., Vollmar, A. M., & Fürst, R. (2011). Flavopiridol protects against inflammation by attenuating leukocyte-endothelial interaction via inhibition of cyclin-dependent kinase 9. ARTERIOSCL THROM VAS, 31(2), 280-288. [2]. http://www.ncbi.nlm.nih.gov/pubmed/21088252?dopt=Citation

Vancouver

Schmerwitz UK, Sass G, Khandoga AG, Joore J, Mayer BA, Berberich N et al. Flavopiridol protects against inflammation by attenuating leukocyte-endothelial interaction via inhibition of cyclin-dependent kinase 9. ARTERIOSCL THROM VAS. 2011;31(2):280-288. 2.

Bibtex

@article{62b8f5c6f4da41ec87e42f4a4acad7a2,
title = "Flavopiridol protects against inflammation by attenuating leukocyte-endothelial interaction via inhibition of cyclin-dependent kinase 9.",
abstract = "The cyclin-dependent kinase (CDK) inhibitor flavopiridol is currently being tested in clinical trials as anticancer drug. Beyond its cell death-inducing action, we hypothesized that flavopiridol affects inflammatory processes. Therefore, we elucidated the action of flavopiridol on leukocyte-endothelial cell interaction and endothelial activation in vivo and in vitro and studied the underlying molecular mechanisms.",
author = "Schmerwitz, {Ulrike K} and Gabriele Sass and Khandoga, {Alexander G} and Jos Joore and Mayer, {Bettina A} and Nina Berberich and Frank Totzke and Fritz Krombach and Gisa Tiegs and Stefan Zahler and Vollmar, {Angelika M} and Robert F{\"u}rst",
year = "2011",
language = "Deutsch",
volume = "31",
pages = "280--288",
journal = "ARTERIOSCL THROM VAS",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

RIS

TY - JOUR

T1 - Flavopiridol protects against inflammation by attenuating leukocyte-endothelial interaction via inhibition of cyclin-dependent kinase 9.

AU - Schmerwitz, Ulrike K

AU - Sass, Gabriele

AU - Khandoga, Alexander G

AU - Joore, Jos

AU - Mayer, Bettina A

AU - Berberich, Nina

AU - Totzke, Frank

AU - Krombach, Fritz

AU - Tiegs, Gisa

AU - Zahler, Stefan

AU - Vollmar, Angelika M

AU - Fürst, Robert

PY - 2011

Y1 - 2011

N2 - The cyclin-dependent kinase (CDK) inhibitor flavopiridol is currently being tested in clinical trials as anticancer drug. Beyond its cell death-inducing action, we hypothesized that flavopiridol affects inflammatory processes. Therefore, we elucidated the action of flavopiridol on leukocyte-endothelial cell interaction and endothelial activation in vivo and in vitro and studied the underlying molecular mechanisms.

AB - The cyclin-dependent kinase (CDK) inhibitor flavopiridol is currently being tested in clinical trials as anticancer drug. Beyond its cell death-inducing action, we hypothesized that flavopiridol affects inflammatory processes. Therefore, we elucidated the action of flavopiridol on leukocyte-endothelial cell interaction and endothelial activation in vivo and in vitro and studied the underlying molecular mechanisms.

M3 - SCORING: Zeitschriftenaufsatz

VL - 31

SP - 280

EP - 288

JO - ARTERIOSCL THROM VAS

JF - ARTERIOSCL THROM VAS

SN - 1079-5642

IS - 2

M1 - 2

ER -